Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Are You Thinking about Taking Part in a Lymphoma Clinical Trial?

Bristol Myers Squibb is committed to lymphoma research by making clinical trials avaialble for all potential patients.

Check Your Eligibility

divider

Lymphoma Clinical Trials

If you are interested in participating in a clinical trial, you have the following options:

Click on the link below each clinical trial to learn more
Select the “Check Your Eligibility” button to see if you are a potential match to a clinical trial and refer yourself to a recruiting trial site
Talk to your doctor

JCAR017-FOL-001

Recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-99282-NHL-001

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-DLBCL-001

Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

NDS-DLBCL-003

Recruiting

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA224-069

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

View Trial Details

CA092-1000

Recruiting

A Rollover Study of CC-122

View Trial Details

divider

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com

Are You Thinking about Taking Part in a Lymphoma Clinical Trial?

Lymphoma Clinical Trials

Let Us Help You Find a Clinical Trial

About

About

NEED HELP?

NEED HELP?